IC-MPGN clinical trials at UCSF

1 research study open to eligible people

IC-MPGN is a kidney disease that leads to inflammation and scarring. UCSF is testing a new medication called Iptacopan to find out if it works well and is safe. The study compares the drug to a placebo in different groups of participants.

Showing trials for

  • Iptacopan in Participants With IC-MPGN

    open to eligible people ages 12-60

    This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex mediated membranoproliferative glomerulonephritis.

    San Francisco, California and other locations

Our lead scientists for IC-MPGN research studies include .

Last updated: